相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review
Dionne Blange et al.
CANCER TREATMENT REVIEWS (2022)
Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene
Kouki Okita et al.
CANCER SCIENCE (2021)
Analysis of Target Molecules towards Anti-cancer Therapeutic Antibodies
Takashi Masuko
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2021)
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target
Natsumi Hayashi et al.
Oncotarget (2021)
Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells
Yuta Hara et al.
CANCER MEDICINE (2020)
Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers
Kouki Okita et al.
Oncotarget (2020)
Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
Hiroki Irie et al.
CANCER SCIENCE (2020)
Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
Byoungsan Choi et al.
ELIFE (2020)
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
Donatella Romaniello et al.
CANCERS (2020)
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
Lena-Christin Conradi et al.
BMC CANCER (2019)
Anti-tumor effects of mAb against l-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes
Shiho Ueda et al.
CANCER SCIENCE (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
Kimio Yonesaka et al.
ONCOGENE (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications
Irene Gullo et al.
PATHOBIOLOGY (2018)
Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer
Jose M. Piulats et al.
Oncotarget (2018)
Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1
Yuta Hara et al.
CANCER SCIENCE (2018)
Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
Troy B. Schedin et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2018)
The roles of microglia macrophages in tumor progression of brain cancer and metastatic disease
Shih-Ying Wu
Frontiers in Bioscience-Landmark (2017)
EMT and MET: necessary or permissive for metastasis?
Mohit Kumar Jolly et al.
MOLECULAR ONCOLOGY (2017)
New Strategies Using Antibody Combinations to increase Cancer Treatment effectiveness
Isabel Corraliza-Gorjon et al.
FRONTIERS IN IMMUNOLOGY (2017)
The impact of age on complications, survival, and cause of death following colon cancer surgery
Christopher T. Aquina et al.
BRITISH JOURNAL OF CANCER (2017)
Colorectal cancer in the world: incidence, mortality and risk factors
Hamidreza Sadeghi Gandomani et al.
BIOMEDICAL RESEARCH AND THERAPY (2017)
Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells
Shogo Okazaki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Live cell imaging shows hepatocyte growth factor-induced Met dimerization
David Koschut et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-)
Kenji Tsuchihashi et al.
CANCER RESEARCH (2016)
HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes
J. Cui et al.
ONCOGENE (2016)
Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role
Qinghua Yuan et al.
PLOS ONE (2015)
FOXM1 Regulated by ERK Pathway Mediates TGF-β1-Induced EMT in NSCLC
Fei-Fei Kong et al.
ONCOLOGY RESEARCH (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).
Paul Haluska et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Momoko Yoshikawa et al.
CANCER RESEARCH (2013)
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
John F. R. Robertson et al.
LANCET ONCOLOGY (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Anti-Tumor Effect against Human Cancer Xenografts by a Fully Human Monoclonal Antibody to a Variant 8-Epitope of CD44R1 Expressed on Cancer Stem Cells
Kazue Masuko et al.
PLOS ONE (2012)
Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
David W. Chan et al.
PLOS ONE (2012)
ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
Byung-Kwon Choi et al.
CANCER MEDICINE (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
J. Tanizaki et al.
BRITISH JOURNAL OF CANCER (2011)
CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc- and Thereby Promotes Tumor Growth
Takatsugu Ishimoto et al.
CANCER CELL (2011)
Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein
Takashi Masuko et al.
CANCER SCIENCE (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Qing Sheng et al.
CANCER CELL (2010)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR plus ) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)
P. A. Kaufman et al.
CANCER RESEARCH (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Fumin Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1
Yoshiya Ohno et al.
CANCER SCIENCE (2008)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
A Citri et al.
EXPERIMENTAL CELL RESEARCH (2003)
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
KA Furge et al.
ONCOGENE (2000)
分享论文
